It does look like these entities are now in VERY good hands with the new president...Harry Lander. Great bio- biotech/chemistry, PHD,MBA, and business education and career experience in both. I like his background with WALLSTREET having started his own securities firm, experience as a securities trader and managing a $1billion hedgefund. All bodes well for us shareholder. IMO.
See below.
Its a matter of time now with the clinical approval at RGBP/BMSN!!
Congrats Koos!
Those of us that have been around for some time have had a lot of frustration and uncertainty over the years. But a crucial milestone has been achieved with the FDA and now with senior management of the companies. GO ENTB/RGBP/BMSN.
As mentioned the NR2F6 gene silencing can apply to feline and canine cancer too so don't be surprised.
Dr. Harry Lander has been appointed assistant dean for research administration at the Medical College.
An alumnus of Cornell University Graduate School of Medical Sciences, Dr. Lander served as a postdoctoral research associate at the Medical College in the departments of biochemistry and pharmacology (1992-1995) and was appointed assistant professor of biochemistry (at the Medical College) and assistant professor in biochemistry and structural biology (at the Graduate School) in 1995, and held those positions until 2000. During this period, his research was supported by five NIH awards and three private grants. He was the author/co-author of more than 30 published articles.
Dr. Lander also has an impressive background in the business and financial arena. Most recently he was president and owner of The Gramercy Group LLC, which specialized in proprietary market making of 50 NASDAQ NMS stocks. Previously, he was managing director of The Lancer Group, a $1 billion hedge fund, and had been a securities trader with Aegis Capital.
In his new role as assistant dean for research administration, Dr. Lander reports to Dr. David Hajjar, executive vice dean of the Medical College and dean of the Graduate School of Medical Sciences. Dr. Lander will help the Medical College move forward with a number of strategic planning efforts. He will oversee the various divisions within the Office of Research and Sponsored Programs (RASP)—including grants and contracts, clinical research administration, technology development and the Research Animal Resource Center (RARC).
Dr. Lander is a member of the American Society of Biochemistry and Molecular Biology; the American Association of Immunologists; and the New York Academy of Sciences.
He received his B.S. in biochemistry and chemistry from the State University of New York at Stony Brook; his Ph.D. in biochemistry from Cornell University Graduate School of Medical Sciences; and his M.B.A. in finance from New York University's Stern School of Business.
